Becton, Dickinson and Company Q2 2026 Earnings Recap

BD's shares rose 3.2% post-earnings, reflecting investor approval of solid revenue growth and margin expansion driven by strong execution across key growth platforms and an upgraded full-year EPS outlook.

Key Takeaways

• Revenue grew 2.6% to $4.7 billion, led by double-digit growth in biologic drug delivery, Advanced Patient Monitoring, PureWick, and Advanced Tissue Regeneration.
• Adjusted operating margin improved to 24.2%, supporting adjusted EPS of $2.90, which exceeded management expectations.
• More than 90% of the portfolio delivered mid-single-digit growth, indicating broad-based strength despite targeted pressure in Alaris, vaccines, and China.
• Management raised full-year adjusted EPS guidance, signaling confidence in the New BD strategy’s ability to drive sustainable growth and improve capital allocation.
• Commercial execution gains included notable share increases in Alaris and accelerated customer adoption in Connected Care and BioPharma Systems.